Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
lidERA: giredestrant versus physician's choice endocrine monotherapy in ER-positive, HER2-negative early breast cancer
CTR20213349Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Started Jun 2022; status: active.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20213349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213349.